Recent Quotes
My Watchlist
Indicators
New Hampshire Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pharmadrug Inc (CSE: PHRX )

0.0250 +0.0150 (+150.00%)
Official Closing Price Updated: 3:36 PM EDT, Aug 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pharmadrug Inc

PharmaTher’s Sairiyo Therapeutics Receives Approval to Initiate a Phase 1 Human Clinical Trial of PD-001 (Reformulated Cepharanthine)
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher’s Sairiyo Therapeutics Submits Clinical Trial Application for Phase 1 Study of Patented Reformulated Cepharanthine
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher’s Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated Cepharanthine
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher’s Sairiyo Therapeutics Inc. Advances Clinical Development of Patented Reformulated Cepharanthine for Phase 1 Study in Australia
From PharmaTher Holdings Ltd.
Via GlobeNewswire
Biotech Veteran David Kideckel Joins the Board of PharmaDrug
Toronto, Ontario--(Newsfile Corp. - August 30, 2021) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a... 
Via Newsfile
Topics Cannabis
Exposures Cannabis Product Safety
PharmaDrug Announces Clinical Research Collaboration with The Johns Hopkins University to Evaluate DMT in a Comparative Clinical Study
Toronto, Ontario--(Newsfile Corp. - August 25, 2021) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a... 
Via Newsfile
Topics Cannabis
Exposures Cannabis Product Safety
PharmaDrug Announces Appointment of Auditor
Toronto, Ontario--(Newsfile Corp. - August 6, 2021) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a... 
Via Newsfile
Topics Cannabis
Exposures Cannabis
PharmaDrug Forms Research Collaboration with Terasaki Institute for Novel Ocular Drug Formulation Program to Deliver DMT and Other Tryptamines to Treat Eye Disease
Unlocking the potential of psychedelics, including DMT, and other tryptamines to treat the significant unmet medical needs of glaucoma patientsPartnering... 
Via Newsfile
Topics Cannabis Law Enforcement
Exposures COVID-19 Cannabis Legal
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.